



# Digital Health Tool for Antibiotic Stewardship A Cluster Randomized Controlled Trial in Tanzania

Rainer Tan, MD, PhD

Rainer.tan@unisante.ch

29. Jahrestagung der Paul-Ehrlich-  
Gesellschaft für Infektionstherapie

18 October 2024





Photo: Magali Rochat

# Drivers of antibiotic prescription



**High mortality & morbidity<sup>1-2</sup>**




**Diagnostic and prescribing uncertainty<sup>3-6</sup>**



**Patient expectations<sup>3,4</sup>**

**Ref:** <sup>1</sup>You, Lancet, 2015; <sup>2</sup>Hug, Lancet GH, 2019; <sup>3</sup>Lopez-Vazquez, J Eval Clin Practice, 2011; <sup>4</sup>Rodrigues, Int J Antimicrobial Agents, 2013; <sup>5</sup>Tonkin-Crine, J Antimicrobial Chemotherapy, 2011; <sup>6</sup>Rezal, Expert Rev Anti Infect Ther. 2015;


# Antibiotic prescription in children: LMIC



Prescribed antibiotics


Cumulative antibiotic exposure

Children 0-5 years (n=438,140)  
45 Low-Middle Income Countries




Children 0-5 years (n=68,826)  
8 Low-Middle Income Countries

A



**65% increase between 2000 to 2015**  
Projected 200% increase by 2030






Photo: Magali Rochat


# Benefits of Digital CDSAs




**Improved quality  
of care** <sup>1-6</sup>



**Cost-effective / net  
savings** <sup>12</sup>



**Reduction in  
antibiotics** <sup>2-3, 7-8</sup>



**Simplifies work** <sup>5, 9-11, 13</sup>




**Improved knowledge  
& skills** <sup>5,9-11</sup>




**Improved clinical  
outcomes** <sup>7,8,14</sup>

**Ref:** <sup>1</sup>Mitchell, BMC Med Inf & Dec, 2013; <sup>2</sup>Rambaud-Althaus, AJTMH, 2017, <sup>3</sup>Bernasconi, PLoS One 2018; <sup>4</sup>Bernasconi, PLoS One 2019; <sup>5</sup>Finette, AJTMH, 2019; <sup>6</sup>Sarrassat, BMC Health Serv Res, 2021; <sup>7</sup>Shao, PLoS One 2015; <sup>8</sup>Keitel, PLoS Med, 2017; <sup>9</sup>Bessat, BMC PH, 2019; <sup>10</sup>Mitchell, J Health Com, 2012; <sup>11</sup>Jensen, Ped Int Child Health, 2020; <sup>12</sup>Cousens, LSHTM, 2018; <sup>13</sup>Shao, BMC Health Serv Res, 2015; <sup>14</sup>Shmitz, BMJ Open, 2022


# Challenges with Digital CDSAs



**Limited scope<sup>1-4</sup>**



**IT software usability and interoperability<sup>2,4,5</sup>**



**Methodological limitations**



**Uptake<sup>2,4</sup>**



**No or little reduction in antibiotic prescription<sup>6-8</sup>**

**Ref:** <sup>1</sup>Bessat, BMC PH, 2019; <sup>2</sup>Shao, BMC Health Serv, 2015; <sup>3</sup>Venkataramani, Int J Qual Health Care, 2017; <sup>4</sup>Jensen, Paediatr Int Child Health, 2020; <sup>5</sup>Chirambo, Int J Med Inf, 2021; <sup>6</sup>Bernasconi, PLoS One 2019; <sup>7</sup>Sarassat, BMC Health Serv Res, 2021; <sup>8</sup>Shmitz, BMJ Open, 2022

ePOCT+  
Clinical Decision Support Algorithm  
**unisanté**



C-Reactive Protein &  
Hemoglobin point-of-care tests



Pulse Oximeter




Dashboard on quality of  
care indicators



Mentorship support

Ref: Tan, PLOS Digital Health, 2023




20 Health Facilities




20 Health Facilities



- 1 Dec 2021 to 31 Oct 2022
- Sick children
- Age 1 day to 15 years




# Co-Primary Endpoint: Day 0 Antibiotic Prescription




Difference -46.4% (95% CI, -57.6% to -35.2%)

Relative Risk 0.35 (95% CI 0.29 to 0.43)

# Co-Primary Safety Endpoint: Day 7 Clinical Failure



# Secondary Endpoints



# Limitations

- Study limitations:
  - Documentation of antibiotic prescription
  - 15% lost to follow for day 7 outcome
- Limitations to widespread implementation:
  - Uptake of ePOCT+
  - IT system integration with other digital health tools
  - Expanded clinical scope for patients aged  $\geq 15$  years




Photo: Magali Rochat

# Conclusion

- Using ePOCT+ safely reduced antibiotic prescription
- Widespread implementation could help address the urgent problem of bacterial antimicrobial resistance
- Further investigations required:
  - Understanding individual impact of mentorship activities and rapid diagnostic tests
  - Cost and greenhouse gas emission analyses
  - Expanded age range to include adults




Photo: Magali Rochat

# Asante! Thank you! Danke!

## ePOCT+ dev team:

K Keitel  
G Levine  
L Luwanda  
C Mangu



H Masanja      V. D'Acremont      N Ntinginya

## MedAL-suite dev team:

A Vonlanthen  
V Faivre  
J Thabard  
I Mtebene  
P Agrea



## Implementation & analysis team:

P Agrea C. Mangu, R Tan, L. Luwanda, I Mtebene, G Kavishe  
T Lotto, H Mkali, G Isdory, I Masanja  
Missing from photo: H Mhagama, M Jorram, S Renggli, A Kulinkina

## Additional Statistical analysis support:

P Taffé  
MA LePogam  
A Kulinkina